18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond

Rodney J. Hicks, Amir Iravani, Shahneen Sandhu

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker and in characterizing response is presented. An added benefit of this approach is the ability to detect immune-related inflammatory reactions, often in advance of severe or life-threatening clinical manifestations.

Original languageEnglish
Pages (from-to)11-22
Number of pages12
JournalPET Clinics
Volume15
Issue number1
DOIs
StatePublished - Jan 2020
Externally publishedYes

Keywords

  • Biomarkers
  • FDG
  • Immunotherapy
  • Melanoma
  • Non-small cell lung cancer
  • PET/CT
  • Therapeutic monitoring

Fingerprint Dive into the research topics of '<sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond'. Together they form a unique fingerprint.

Cite this